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Molecular Recognition by LARGE Is Essential
for Expression of Functional Dystroglycan
indicating that the integrity of this complex is crucial for
muscle cell viability (Cohn and Campbell, 2000; Burton
and Davies, 2002; Tome´, 1999). DG is encoded by a
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-DG is comprised of three distinct domains: theSweden
N-terminal, the mucin-like, and the C-terminal (Figure
1A). The N- and C-terminal domains are globular and
are joined by a central mucin-like domain that is highlySummary
glycosylated by O-linked oligosaccharides (Brancaccio
et al., 1995, 1997). Sugar chain moieties comprise up toReduced ligand binding activity of -dystroglycan is
two-thirds of the molecular mass of -DG (Ibraghimov-associated with muscle and central nervous system
Beskrovnaya et al., 1992; Ervasti and Campbell, 1993).pathogenesis in a growing number of muscular dystro-
Certain sugar chain structures of-DG play an importantphies. Posttranslational processing of -dystroglycan
role in its binding to ligand proteins (Yamada et al.,is generally accepted to be critical for the expression
1996; Chiba et al., 1997). Thus, the mucin-like domainof functional dystroglycan. Here we show that both
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components, such as laminin-1, laminin-2, agrin, neu-like domain of -dystroglycan are essential for high-
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-DG (Ibraghimov-Beskrovnaya et al., 1992; Sunada etmodification of -dystroglycan by glycosyltransfer-
al., 1994; Bowe et al., 1994; Sugita et al., 2001; Peng etase, LARGE, occurs within the mucin-like domain, but
al., 1998). Each of these ligands has laminin G (LG)-the N-terminal domain interacts with LARGE, defining
like domains that mediate their interaction with -DGan intracellular enzyme-substrate recognition motif
(Hohenester et al., 1999). However, the functional do-necessary to initiate functional glycosylation. Gene re-
mains of -DG have not been characterized systemati-
placement in dystroglycan-deficient muscle demon-
cally, and to date, the nature and location of the laminin
strates that the dystroglycan C-terminal domain is binding site in -DG remains elusive.
sufficient only for dystrophin-glycoprotein complex Mutations in known or putative glycosyltransferase
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molecular recognition of dystroglycan by LARGE is a (FKRP) in congenital muscular dystrophy 1C (MDC1C);
key determinant in the biosynthetic pathway to pro- POMGnT1 in muscle-eye-brain disease (MEB); POMT1
duce mature and functional dystroglycan. in Walker-Warburg syndrome (WWS); and LARGE in
congenital muscular dystrophy 1D (MDC1D), as well as
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cellular matrix (ECM) ligands leads to muscular dystrophy, (Michele et al., 2002; Hayashi et al., 2001; Kano et al.,
2002). These findings indicate that the posttranslational
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Figure 1. Analysis of -DG Functional Domains
(A) Schematic representation of DG deletion mutant proteins. -DG is composed of a signal peptide (SP, amino acids 1–29), an N-terminal
domain (amino acids 30–316), a mucin-like domain (amino acids 317–485), and a C-terminal domain (amino acids 486–653). The disulfide bond
is shown by S-S and potential N-glycosylation sites are indicated by arrowheads. The hatched box represents -DG.
(B) The N-terminal domain of -DG is necessary for cell surface laminin and perlecan organization. Laminin-1 (Lam) and perlecan (Per) form
clusters of plaque-like morphology on the surface of cells expressing DG-WT and DG-G. The scale bar represents 10 m.
(C) Both the N-terminal domain and the first half of the mucin-like domain (amino acids 30–408) of -DG are necessary for laminin binding.
Western blotting and laminin overlay (O/L) assays show that laminin-1 binds to DG-WT and DG-G.
muscle and central nervous system pathology (Michele perhaps functionally distinct glycosyltransferase-like
domains (Grewal et al., 2001; Peyrard et al., 1999), canet al., 2002). Recently, we have found that the overex-
pression of LARGE, which contains two structurally and bypass defects of -DG laminin receptor function in
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WWS, MEB, and FCMD patients’ cells (Barresi et al., transfecting TSA201 cells. The majority of the expressed
full-length fusion protein (DGFc5) was secreted as a2004), suggesting a novel and flexible pathway for ex-
pression of functional DG. 100–120 kDa protein into the culture media although
some was detected in the cell lysate. We observed, byIn order to better understand the posttranslational
processing pathway for expression of functional DG, we blot-overlay assay, that laminin-1 bound to the secreted
DGFc5, but not to DGFc5 in the cell lysate (Figure 2A).characterized the functional domains of DG in vitro and
in vivo. We first demonstrate that in addition to the first Interestingly, the species of DGFc5 that binds to laminin
migrates slower than that stained by Coomassie bluehalf of the mucin-like domain, the N-terminal domain of
-DG is essential for the production of functional -DG (CB). Antibody FPD, against the core protein of -DG,
identified broader bands than those stained by CB (Fig-as a laminin receptor. We provide evidence of a molecu-
lar interaction between LARGE and the N-terminal do- ure 2B). Laminin and IIH6 reacted to the slow migrating
species of the FPD-reactive bands (data not shown).main of -DG, and these data indicate that LARGE uses
this N-terminal domain to recognize DG as a substrate. This broad appearance of the fusion protein suggests
extensive posttranslational modification, as is the caseFurthermore, we show evidence that the N-terminal do-
main of DG is cleaved by convertase-like activity, but with native -DG in skeletal muscle (Ervasti and Camp-
bell, 1991). Enzymatic deglycosylation slightly decreasedthe cleavage does not affect DG ligand binding activity.
Therefore, the data indicate that with regard to ligand the molecular mass of DGFc5 and did not affect laminin
binding activity (Figure 2B). However, chemical deglyco-binding, the N-terminal domain of -DG is necessary
only for intracellular formation of an enzyme-substrate sylation greatly reduced the molecular mass and abol-
ished laminin binding activity. These results are consis-intermediate between DG and LARGE, while the C-ter-
minal domain of - and/or -DG mediates the assembly tent with previous observations that the sugar chain
structure of -DG is necessary for the interaction withof the DGC at the sarcolemma. Significantly, using viral
gene transfer to skeletal muscle-specific DG null mice, laminin (Ervasti and Campbell, 1993). It is evident that
only a small population in the DGFc5 preparations pos-we provide in vivo evidence that the disruption of the
DG-laminin linkage, through the absence of the critical sess the specific carbohydrate modification required
for ligand binding activity. Taken together, these dataglycosylation or LARGE recognition, is central to muscle
cell degeneration in muscular dystrophy. indicate that strict posttranslational glycosylation is
necessary for the interaction between -DG and laminin.
To confirm that DGFc5 conserves the ligand bindingResults
properties of native-DG, we demonstrated that DGFc5,
when compared to native-DG, has similar laminin bind-Posttranslational Modification Regulates Laminin
ing affinity (Figure 2C), can quantitatively compete lami-Receptor Function of DG
nin binding to native -DG (data not shown), and showsTo examine the nature of the -DG-laminin interactions,
similar ligand selectivity by nonlabeled ligand competi-we generated a set of adenovirus (AdV) constructs with
tion assays (Figure 2D).deletions in the N-terminal and/or the mucin-like domain
of -DG (Figure 1A). These deletion constructs, when
expressed in embryonic stem (ES) cells, can properly LARGE-Dependent Functional
Modification of -DGtarget - and -DG proteins to the cell surface mem-
brane (Kunz et al., 2001). First, we performed a laminin-1 We recently demonstrated that forced expression of
LARGE produced glycan-rich -DG species and re-and perlecan clustering assay on DG null (DG/) ES
cells after infection with each AdV construct to define stored its function as a laminin receptor in FCMD, MEB,
and WWS patients’ cells (Berresi et al., 2004). We investi-the DG domains necessary for DG-mediated basement
membrane assembly. Laminin-1 and perlecan formed gated the molecular mechanism for LARGE-dependent
functional modification of DG using DGFc fusion pro-clusters, which consolidated into plaque-like morpholo-
gies on the surface of ES cells expressing DG-WT or teins. Several deletion constructs of DGFc proteins were
generated and expressed in TSA201 cells (Figure 3A).DG-G. No clusters were observed on the cells express-
ing DG-I, DG-D, DG-E, or DG-F (Figure 1B). Next, the Ligand overlay assays on these fusion proteins further
confirmed our previous results in ES cells: both thelaminin binding domain was characterized by blot over-
lay assay. Because antibodies against -DG do not rec- N-terminal domain and the first half of the mucin-like
domain are essential for DG function as an ECM-recep-ognize all of the deletion mutants, the protein amount
was adjusted by immunoreactivity against -DG (Figure tor (Figure S1 on the Cell website). Furthermore, adeno-
viral expression of LARGE with each DGFc fusion protein1C). Laminin-1 bound to DG-WT and DG-G (Figure 1C).
The monoclonal antibody IIH6, whose epitope is sensi- increased reactivity to IIH6 and laminin-1 binding in the
secreted forms of DGFc3 and DGFc5, but not in DGFc2tive to the glycosylation status of -DG (Ervasti and
Campbell, 1993), also detected only DG-WT and DG-G. and DGFc6 (Figure 3B). However, in cell lysates, regard-
less of LARGE overexpression, we did not observe sig-Unexpectedly, the results demonstrated that in addition
to the N-terminal half of the mucin-like domain, the nificant reactivity of any DGFc proteins to laminin-1 or
IIH6 even when detection sensitivity was increased and/whole N-terminal domain of -DG is necessary for lami-
nin and IIH6 binding as well as laminin-1 and perlecan or the fusion protein was loaded in equal amounts com-
pared to the secreted DGFc protein experiments. A solidorganization on the cell surface.
To further investigate the interaction between -DG phase laminin-1 binding assay on secreted DGFc5 dem-
onstrated that LARGE modification quantitatively in-and laminin, we generated full-length and truncated
-DG molecules as IgG Fc fusion proteins (DGFc) by creased the laminin-1 binding activity (Figure 3C). Al-
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Figure 2. Expression of Full-Length -DG-
IgG Fc Fusion Protein (DGFc5) and Its Inter-
action with Laminin
DGFc5 was purified from the conditioned me-
dium or cell lysate. Arrowheads indicate con-
taminated immunoglobulin light chain, heavy
chain, and heavy chain dimer. O/L, overlay.
(A) Laminin-1 binds to DGFc5 in conditioned
medium but does not bind to that in cell ly-
sate. A population of DGFc5 to which lami-
nin-1 binds migrates more slowly than that
stained by CB. Lane 1, mock transfection;
lane 2, transfection with DGFc5. A schematic
representation of DGFc5 is shown at the top
of panel (A). Black boxes indicate the Fc
portion.
(B) Glycosylation is essential for laminin bind-
ing activity of DGFc5. DGFc5 was deglycosy-
lated either enzymatically or chemically. By
chemical deglycosylation, the molecular
mass of DGFc5 is greatly reduced, and lami-
nin binding is abolished. Lane 1, untreated
sample; lane 2, treated sample for deglyco-
sylation.
(C) Binding of laminin-1 to DGFc5 (closed cir-
cle) and native -DG (open circle). By nonlin-
ear regression analysis, the dissociation con-
stants of DGFc5 and native -DG are
estimated to be 1.1  0.1 and 0.4  0.1
nM, respectively.
(D) DGFc5 represents similar ligand selectiv-
ity to native-DG. Competitive binding of bio-
tinylated laminin-1 to native -DG (open cir-
cle) or DGFc5 (closed circle) was measured
in the presence of nonlabeled laminin-1, lami-
nin-2, and agrin. All nonlabeled ligands com-
pete the binding of biotinylated laminin-1 to
both native -DG and DGFc5.
though DGFc6 contains the entire mucin-like domain, A molecular weight shift following protease inhibition
was also found in secreted DGFc3 and DGFc5, but notwe did not see any functional modification of DGFc6
even after the LARGE overexpression, suggesting that in DGFc6 (data not shown). CMK treatment caused se-
creted DGFc5 to migrate around 150 kDa and becomethe N-terminal domain is required for the functional mod-
ification by either LARGE or other intrinsic glycosyltrans- reactive to an antibody to an N-terminal peptide of -DG
(rabbit 73) (Figure 4A). Without the CMK treatment, noferases. Notably, the secreted form of DGFc5 and
DGFc6 migrated with similar molecular weight on SDS- significant reactivity to rabbit 73 was obtained with
DGFc5 prepared from cell culture media. On the otherPAGE, and the majority of DGFc2 prepared from condi-
tioned medium seemed to be degraded. These findings hand, the DGFc5 preparations from cell lysate showed
reactivity against rabbit 73 regardless of CMK treatmentled us to hypothesize that the N-terminal domain was
proteolytically processed. We found that culturing (Figure 4A). These data suggest that a convertase-like
activity processes the N-terminal domain of -DG as itTSA201 cells expressing DGFc2 in the presence of dec-
anoyl-Arg-Val-Lys-Arg-CMK (CMK), an inhibitor for pro- is secreted from cells or in the extracellular environment.
N-terminal amino acid sequence analyses of DGFc5protein convertases (endoprotease family), prevented
degradation of DGFc2. Accordingly, the secreted DGFc2 from CMK-treated cells and full-length DGFc5 cleaved
by furin in vitro revealed that a convertase-like activitymigrated at the same molecular size (approximately 65
kDa) as DGFc2 prepared from cell lysate. Neither prepa- cleaves -DG between Arg312 and Gln313 (Figure S2 on
the Cell website).ration showed any detectable laminin binding activity,
with or without LARGE coexpression (data not shown). Our evidence of proteolytic processing of the N-ter-
minal domain of secreted DG excluded the possibilityThese data also support previous findings that essential
glycosylation indeed occurs in the mucin-like domain. that the ternary structure of the N-terminal domain is
Functional Domains in Dystroglycan Processing
957
Figure 3. LARGE-Dependent Glycosylation Requires the N-Terminal Half of -DG
(A) Schematic representation of deletion mutants of DGFc proteins.
(B) The N-terminal domain and the first half of the mucin-like domain of -DG are necessary for LARGE-dependent glycosylation. Western
blotting and a laminin overlay (O/L) assay shows that DGFc3 and DGFc5 are functionally glycosylated by LARGE. Neither the N-terminal nor
the mucin-like domain itself is sufficient for the functional glycosylation by LARGE and/or intrinsic glycosyltransferases.
(C) LARGE-dependent glycosylation of DGFc5 increases laminin binding activity. By nonlinear regression analysis, the dissociation constants
of DGFc5 (open triangles) and LARGE-modified DGFc5 (closed triangles) to laminin-1 are estimated to be 3.1 1.1 and 1.6 0.1 nM, respectively.
directly required for laminin binding to the mucin-like of -DG is recognized by LARGE to form the enzyme-
substrate intermediate, which is necessary for the sub-domain. Since DGFc5 isolated from cells contains the
N-terminal domain, we hypothesized that the N-terminal sequent glycosylation on the first half of the mucin-like
domain. The N-terminal domain is then proteolyticallydomain may be required intracellularly for transient rec-
ognition by glycosyltransferases to form an enzyme- cleaved after the glycosylation occurs.
substrate intermediate. To test this hypothesis, we ex-
amined molecular interactions between LARGE and In Vivo Evidence for Significance
of DG-LARGE InteractionDGFc proteins. Protein A affinity beads coupled to DGFc
proteins were incubated with LARGE-overexpressed In order to determine the significance of the molecular
recognition of the N-terminal domain by LARGE, and theTSA201 cell lysates. Bound materials were eluted with
Laemmli sample buffer (LSB) and analyzed by Western functional glycosylation of -DG in vivo, we expressed
deletion mutants of DG in skeletal muscle of MCK-DGblotting using an anti-LARGE antibody (Figure 4B). We
found that LARGE interacted with DGFc2 (lane 2) and null mice in which the endogenous DG gene is selec-
tively ablated in striated muscle. MCK-DG null miceDGFc5 prepared from cell lysate (lane 3). Importantly,
although the secreted form of DGFc5 did not bind show concomitant loss of sarcoglycans and sarcospan
and develop muscular dystrophy at 4–5 weeks of ageLARGE (lane 4), inhibition of proteolytic cleavage with
CMK successfully reconstituted the DGFc5-LARGE com- (Cohn et al., 2002). Five weeks after viral gene transfer,
more than 80% of the muscle fibers were transducedplex (lane 5). Mature glycosylation does not seem to
affect the interaction between -DG and LARGE. To- and converted to DG positive in each of the injected
mice (Figure 5). Interestingly, each of the expressedgether, these data suggest that the N-terminal domain
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et al., 2002). However, after expression of DG-D, DG-E,
DG-F, or DG-H, fibrosis and fatty infiltration were com-
monly observed (Figure 6A). In contrast, expression of
DG-WT or DG-G, proteins that bind to laminin, com-
pletely rescued the mouse from dystrophic pathology
(Figure 6A). Quantitative morphometric analyses were
performed by recording the percentage of fibers with
centrally located nuclei and fiber diameter variability,
which reflect ongoing muscle regeneration and are both
increased in muscular dystrophy. MCK-DG null mice
injected with saline (Mock) or expressing DG-I, DG-D,
DG-E, DG-F, or DG-H had a significantly higher percent-
age of fibers with central nuclei and fiber diameter vari-
ability than control Cre-negative mice. The expression
of DG-WT or DG-G in mutant mice prevented the in-
crease in central nucleation and fiber diameter variability
(Figures 6B and 6C). Taken together, these results pro-
vide in vivo evidence that the DGC assembly mediated
by -DG with the C-terminal domain of -DG is not
sufficient and that the -DG-laminin interaction is crucial
to prevent muscle cell degeneration. These results dem-
onstrate that the molecular recognition of -DG by
LARGE through the N-terminal domain of -DG is essen-
tial for the subsequent functional glycosylation that un-
derlies the pathology of several forms of muscular dys-
trophy.
Discussion
In the present study, we dissected the functional do-Figure 4. Mechanism for Glycosylation of -DG by LARGE
mains of DG necessary for ECM protein organization,(A) Proteolytical processing of the N-terminal domain of -DG. West-
ligand interactions, DGC assembly, and recognition byern blotting analysis with antibodies to the Fc or the N-terminal
glycosyltransferases. We provide strong evidence, sum-sequence of -DG (rbt73) reveal that the secreted form of DGFc5
lacks its N-terminal domain. DGFc5 in cell lysates contains its marized below and in Figure 7, for a direct role of the
N-terminal domain. Treatment with a convertase inhibitor, CMK, ECM ligand binding domain of -DG in the pathogenesis
prevents proteolytic processing of the N-terminal domain of the of muscular dystrophy and a unique processing pathway
secreted form of DGFc5. (B) Molecular interaction between -DG
for expression of functional DG. The N-terminal domainand LARGE. The following DGFc-protein A beads were prepared
of -DG serves as an intracellular substrate recognitionand then incubated with LARGE-expressing TSA201 cell lysate: Fc
site for LARGE, which initiates subsequent functional(cell lysate), DGFc2 (cell lysate), DGFc5 (cell lysate), DGFc5 (me-
dium), and DGFc5 (CMK-treated, medium). Western blotting with glycosylation of -DG. The glycosylation, which is es-
anti-LARGE antibody demonstrates that LARGE recognizes the sential for ligand binding and cell surface laminin/per-
N-terminal domain of -DG to form an enzyme-substrate intermedi- lecan organization, takes place within the first half of
ate complex.
mucin-like domain. -DG with the C-terminal domain of
-DG mediates the DGC assembly. This assembly is not
sufficient to prevent muscular dystrophy. Rather, theDG proteins (DG-WT, DG-I, DG-D, DG-E, DG-F, DG-G)
-DG-laminin linkage is necessary to prevent musclerestored the DGC assembly at the sarcolemma including
cell degeneration. These findings demonstrate in vitrosarcoglycans and sarcospan. The expression of a
and in vivo that molecular recognition of DG by LARGEshorter DG-H protein lacking the entire N-terminal and
is a key determinant of DG functional expression.mucin-like domains of -DG also restored the DGC as-
sembly. In Figure 5, the expression profile is represented
by DG-E and DG-H. Dystrophin and 1-syntrophin, Mechanism of Posttranslational Modification
of -DG for ECM Bindingwhich are preserved in MCK-DG null mice, were also
normally expressed in these muscles. These results pro- DG-mediated formation of laminin clusters on the cell
surface is thought to be critical for embryonic basementvide novel evidence that the C-terminal domain of -DG
and/or -DG mediate the stable assembly of the DGC membrane assembly (Williamson et al., 1997; Henry and
Campbell, 1998). We observed laminin clustering on theat the sarcolemma.
Surprisingly, hematoxylin-eosin staining revealed that surface of DG-WT- or DG-G-expressing ES cells (Figure
1). In addition, only these two proteins show lamininexpression of DG-I, DG-D, DG-E, DG-F, or DG-H exacer-
bated the dystrophic phenotype of the mutant mice in binding activity, indicating that the N-terminal domain
and the N-terminal half of the mucin-like domain (aminospite of full restoration of the DGC (Figure 6). The patho-
logical phenotype of the MCK-DG null mouse includes acids 30–408) are required for functional expression of
DG as a laminin receptor. This observation is consistentnumerous regenerating fibers in skeletal muscle with no
evidence of tissue fibrosis and/or fatty infiltration (Cohn with the “DG-facilitated laminin network model,” which
Functional Domains in Dystroglycan Processing
959
Figure 5. Restoration of the DGC in Skeletal
Muscle of MCK-DG Null Mice Expressing DG
Deletion Mutant Proteins
The C-terminal domain of -DG and/or -DG
is responsible for the DGC assembly. The
DGC assembly was examined by immunoflu-
orescence analysis after expression of dele-
tion mutants of DG in vivo. The figure shows
DG-E- and DG-H-injected skeletal muscle,
which represent all constructs tested. All the
DGC components are restored at the sarco-
lemma after gene transfer. Equivalent results
were obtained by expression of DG-WT, DG-I,
DG-D, DG-F, or DG-G. SG, sarcoglycan;
SSPN, sarcospan; DYS, dystrophin; and
SYN, syntrophin.
proposes that both laminin self-association and DG are the population of DGFc5 with a higher molecular weight
and little CB staining may be a mature form of -DGnecessary for the formation of a laminin network on the
cell surface (Colognato et al., 1999). Myotubes differenti- because both laminin and IIH6 bind only to this portion.
In this context, DGFc5 isolated from cells seems to beated from WWS and FCMD patients fail to form laminin
clusters (Barresi et al., 2004). After LARGE expression immature. Players for DG glycosylation appear, or are
hypothesized, to locate in the Golgi apparatus (Esapain these cells, restoration of laminin organization is ob-
served, suggesting that DG function is also required for et al., 2003). These observations together suggest that
DGFc5 matures intracellularly in the Golgi apparatuslaminin organization in skeletal muscle cells.
Previous studies suggest that -DG in skeletal muscle and is secreted immediately so that there is very little
detected in the cell lysate by laminin overlay assay.is extensively glycosylated, thus contributing to the
broad appearance of -DG on Western blot (Ervasti and However, full maturation, at least in TSA201 cells, is not
essential for secretion of -DG into the extracellular en-Campbell, 1991). Consistent with this notion, we ob-
served a broad appearance of DGFc5 secreted into cul- vironment.
Recently, we found that overexpression of LARGE inture media (Figures 2 and 3). The population of DGFc5
stained by CB may represent immature DG in terms cells from WWS, MEB, and FCMD patients induced the
synthesis of an -DG species enriched in glycans withof functional posttranslational modification. In contrast,
Cell
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Figure 6. Histological Analysis of MCK-DG Null Muscles after Expression of DG Deletion Mutant Proteins
Laminin binding activity is essential for maintaining muscle cell integrity.
(A) The pathological phenotype after expression of deletion mutants of DG in vivo was examined by hematoxylin-eosin staining. Numerous
regenerating fibers with central nuclei are seen in MCK-DG null mice with mock injection (open arrowhead). In the muscles expressing DG-I,
DG-D, DG-E, DG-F, or DG-H, fibrous connective tissue is increased (arrow), and fatty infiltration is detected (closed arrowhead). In sharp
contrast, the muscles expressing DG-WT and DG-G are fully rescued from dystrophic pathology.
(B) The percentage of myofibers with centrally located nuclei in the MCK-DG null mice expressing DG-WT and DG-G was not statistically
different from that in the control mice.
(C) The variability of myofiber diameter in the MCK-DG null mice expressing DG-WT and DG-G was decreased and not statistically different
from that of the control mice. The bar in the box represents the mean diameter. The boxes indicate the 25 and 75 percentile values, and the
error bars represent the 10 and 90 percentile values.
high affinity for extracellular ligands, leading to restora- viable therapeutic strategy for glycosyltransferase-defi-
cient muscular dystrophies. In the present report, wetion of -DG as a functional laminin receptor (Barresi et
al., 2004). These findings indicate that a LARGE-depen- observed a direct increase of laminin binding activity
in DGFc5 after LARGE expression (Figure 3). Laminindent posttranslational pathway can be a target for a
Functional Domains in Dystroglycan Processing
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Figure 7. Multistep Molecular Pathway for the Functional Expression of DG
Distinct domains are responsible for each step of posttranslational modification of DG. Important domains in each step are represented in
dark red. The N-terminal domain and the first half of the mucin-like domain are necessary for functional glycosylation. The N-terminal domain
is recognized by LARGE. LARGE-dependent modification takes place within the first half of the mucin-like domain. The C-terminal domain
and/or -DG is responsible for the sarcoglycan (SG) assembly. All steps are necessary for the functional expression of DG to maintain muscle
cell integrity and basement membrane assembly.
overlays indicated that the N-terminal domain is a pre- (Barresi et al., 2004). This seems to be a unique mecha-
nism in terms of substrate recognition. That is, LARGErequisite for LARGE-dependent functional glycosylation
on the mucin-like domain of -DG (Figure 3) as is the recognizes amino acid sequences located in a different
part of the protein from the acceptor region for the glyco-case with intrinsic glycosyltransferases in ES and
TSA201 cells (Figure 1; see also Figure S1 available on conjugate. It is also suggested that the intrinsic glycosyl-
transferases involved in -DG modification in TSA201the Cell website at http://www.cell.com/cgi/content/full/
117/7/953/DC1/). The involvement of the N-terminal do- cells also recognize the N-terminal domain. Therefore,
we conclude that the N-terminal domain of -DG deter-main in the functional expression of-DG was of particu-
lar interest. This observation first raised the possibility mines specificity for glycosylation on the mucin-like
domain.that, in addition to the sugar chain moieties, the core
protein structure in the N-terminal domain is also impor- We demonstrated that the N-terminal domain is pro-
teolytically processed by intrinsic convertase-like activ-tant in the interaction with laminin. At first, we specu-
lated that the N-terminal domain acts as a regulator by ity after the functional glycosylation of -DG. Because
cellular DGFc5 contains the N-terminal domain, the pro-providing a tertiary structure to promote accessibility of
the receptor sugar chains in the mucin-like domain. In cessing seems to occur in the extracellular space or
immediately preceding secretion. The higher molecularaddition, the core protein structure might provide a dis-
tinct binding domain, which directly interacts with its weight of the secreted form of DGFc5 with CMK treat-
ment compared to the cell lysate form represents theligands in cooperation with the mucin-like domain. How-
ever, surprisingly, the N-terminal sequence analysis re- inclusion of the uncleaved peptide (amino acid residues
30–312) plus the additional glycosylation as the proteinvealed that mature -DG lacks the N-terminal domain
(Figure 4; Figure S2 on the Cell website). On the other proceeds through the secretory pathway. This proteo-
lytic processing of the N-terminal domain is thought tohand, Western blotting analysis with rabbit 73 showed
that intracellular DGFc5 contains the N-terminal domain be a common feature of DG posttranslational modifica-
tion for the following reasons: We found a molecular(Figure 4). Therefore, we proposed the alternative hy-
pothesis that the N-terminal domain may be required for weight shift in -DG on SDS-PAGE when mouse myo-
blast C2C12 and rat Schwannoma RT4 cells were cul-intracellular substrate recognition by essential enzymes
that glycosylate -DG and formation of a transient en- tured in the presence of CMK. This CMK effect was not
observed in mouse tissue preparations. The in vitro furinzyme-substrate intermediate. Indeed, we demonstrated
an interaction between the N-terminal domain of -DG treatment of purified -DG did not show any changes
in its molecular weight. Although the physiological roleand LARGE (Figure 4). This LARGE-DG intermediate may
be critical to the specificity for -DG functional glycosyl- of the N-terminal domain processing is unclear, it pro-
vides clear evidence that the N-terminal domain is notation because we observed specific increases in glyco-
sylation of -DG in cells and tissues overexpressing directly involved in ligand binding. We did not observe
significant differences in ligand binding affinity and max-LARGE, and the high level of LARGE expression did not
cause muscle pathology in wild-type skeletal muscle imum binding for DGFc5 after CMK treatment (data not
Cell
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shown). The N-terminal domain of -DG has been re- et al., 1993; Duclos et al., 1998a, 1998b; Holt et al., 1998;
Durbeej et al., 2000; Matsumura et al., 2003). Thus, it isported to interact with some extracellular matrix pro-
teins itself (Hall et al., 2003); therefore, the processed possible that the secondary disruption of the DG-laminin
linkage due to the concomitant reduction of-DG, ratherN-terminal domain might still be associated in the ECM.
Another possibility is that even after processing in vivo, than primary deficiency of dystrophin or sarcoglycans,
is causative for the muscle cell degeneration in DMDthe N-terminal domain might still be associated with the
core protein since rotary shadowing electron micros- and LGMD. To facilitate the understanding of the patho-
genesis of these muscular dystrophies with secondarycopy suggested the dumbbell-like architecture of -DG
consists of two globular structures (Brancaccio et al., DGC disruption, it is of particular importance to generate
animal models in which a certain protein component1995, 1997).
or certain protein linkage alone is selectively disrupted
within a normally expressed DGC. From this point ofImplication of the Laminin Binding Activity of DG
view, our MCK-DG null mice expressing mutant DG pro-in the Pathogenesis of Muscular Dystrophy
teins provide an example of a unique model in whichOur data demonstrate that the C-terminal half of DG is
-DG-laminin interactions are selectively lost and pro-involved in the assembly of the sarcoglycan-sarcospan
vide the opportunity to specifically define the criticalcomplex (Figure 5). Formation of the sarcoglycan com-
role of these interactions in the prevention of muscleplex has been proposed to take place during trafficking
disease. Taken together, we propose that the disruptionfrom the Golgi to plasma membrane (Noguchi et al.,
of the DG-laminin linkage is a common, central pathway2000). Our results suggest that full restoration of DGC
leading to the muscle cell pathogenesis in the muscularassembly in MCK-DG null skeletal muscle is not suffi-
dystrophies. Overall, we propose that molecular recog-cient for the rescue of dystrophic pathology and, rather,
nition of DG by LARGE is a key determinant in the biosyn-the-DG-laminin linkage is crucial to prevent the dystro-
thetic pathway to produce a mature and functional DG.phic phenotype (Figures 5 and 6). In addition, the data
provide clear in vivo evidence that lack of protein recog-
Experimental Proceduresnition by LARGE, and perhaps other glycosyltransfer-
ases, through the N-terminal domain of -DG and the
Antibodiessubsequent absence of -DG-laminin interactions are
Antibodies to -DG (IIH6, FPD, and GT20ADG), and -DG were
sufficient to cause muscular degeneration in these dis- described previously (Ibraghimov-Beskrovnaya et al., 1992; Michele
orders. Although mutations of the DG gene have not et al., 2002; Williamson et al., 1997). Antibodies against -sarcogly-
been reported, it is possible that mutation in the can, -sarcoglycan, sarcospan, dystrophin and -sarcoglycan were
described elsewhere (Duclos et al., 1998b). Antibodies againstN-terminal domain of -DG causes abnormal glycosyla-
LARGE and -DG N-terminal fragment (rabbit 73) were raised intion of -DG.
rabbits. Synthetic peptides corresponding to the C-terminal se-Interestingly, the expression of non-laminin binding
quence of mouse LARGE (C-YGFAALKYLTAENN) and the N-terminal
DG proteins exacerbated the dystrophic pathology in sequence of rabbit DG (HWPSEPSEAVRDWEN) were used as anti-
MCK-DG null mice. MCK-DG null mice have low level gens, respectively. Specificity of anti-LARGE antibody was con-
expression of endogenous DG due to the re-expression firmed by Western blotting using TSA201 cell lysates prepared be-
fore and after LARGE overexpression. Monoclonal antibody againstof DG from satellite cells undergoing regeneration. This
-sarcoglycan, 21B5, was generated in collaboration with Dr. Louiseexpression of DG in satellite cells allows efficient regen-
Anderson. Anti-laminin and anti-heparan sulfate proteoglycan (per-eration, causing the nonprogressive phenotype of these
lecan) antibodies were purchased from Sigma and Chemicon Inter-
mice (Cohn et al., 2002). The regenerating capacities of national Inc, respectively. Antibodies against laminin 2-chain, lami-
mdx (dystrophin null) and sarcoglycan null mice are less nin 1-chain and 1 syntrophin were kind gifts from Drs. Peter
than MCK-DG null mice (Cohn et al., 2002). It is possible Yurchenco, Lydia Sorokin and Stanley Froehner, respectively. Per-
oxidase conjugated secondary antibodies were obtained fromthat these AdV constructs also transduced satellite cells
Roche. Biotinylated anti-human IgG was from Vector. Cy3 and FITCand truncated DG proteins affected regenerative capac-
conjugated secondary antibodies were from Jackson Immuno Re-ity. Overexpression of DG mutants without laminin bind-
search. Peroxidase conjugated avidin was from Pierce.
ing activity may be competing with the residual endoge-
nous DG for intracellular binding partners, which are
Expression and Purification of Recombinantinvolved in signal transduction (Henry and Campbell,
-DG-IgG Fc Fusion Proteins
1999). This dominant-negative effect in satellite cells Construction of -DG-IgG Fc fusion proteins were described else-
may impair the repair mechanism and eventually lead where (Kunz et al., 2001). Construction of DGFc6 is shown in the
Supplemental Data available on the Cell website. TSA201 cells wereto fibrosis and fat replacement in skeletal muscle.
grown in Dulbecco’s modified eagle media (DMEM) supplementedIn the last decade, primary genetic defects in the DGC
with 10% fetal bovine serum (FBS), 2 mM L-glutamine and penicillin-were identified in several forms of muscular dystrophy.
streptomycin (GIBCO-BRL). Cells were transiently transfected usingThese include dystrophin, -, -, -, and -sarcoglycan,
FuGene 6 (Roche). The conditioned medium and the cells were
which cause Duchenne/Becker muscular dystrophy collected 4 days after transfection unless stated otherwise. For
(DMD/BMD), limb-girdle muscular dystrophies (LGMD) CMK-treatment, after the transfection, cells were cultured in the
presence of 20 M CMK (ALEXIS) for 2-4 days. The cells were lysedtype 2D, 2E, 2C, and 2F, respectively (for review, see
in Buffer A (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,Cohn and Campbell [2000]). However, the exact molecu-
0.6 g/ml of pepstatin A, 0.5 g/ml of aprotinin, 0.5 g/ml of leupep-lar mechanisms through which these primary defects
tin, 0.75 mM of benzamidine, 0.1 mM of PMSF, 0.4 g/ml of calpainlead to muscle cell death remain elusive because other
inhibitor and 0.4 g/ml of calpeptin) for 2 hr at 4C and the extracts
DGC components including -DG are lost en bloc or are were collected by centrifugation at 20,000 	 g for 10 min. The
at least severely reduced as a result of each primary cell extracts and conditioned medium were incubated with protein
A-agarose (Santa Cruz) overnight at 4C. The beads were washeddefect in these disorders (Ervasti et al., 1990; Ohlendieck
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extensively with Buffer A and the bound DGFc proteins were eluted brock for expert technical assistance; Charles Lovig and The Univer-
sity of Iowa Hybridoma Facility for preparing monoclonal antibodyby 100 mM glycine-HCl, pH 2.8, or by boiling in LSB.
IIH6; Peter Yurchenco (Robert Johnson Medical School), Lydia Soro-
kin (University of Erlangen), Stanley Froehner (University of Washing-Deglycosylation Experiments
ton) and Louise Anderson (Novocastra) for providing antibodies;Thirty l of purified DGFc5 preparations were boiled for 5 min in
The University of Iowa Gene Transfer Vector Core, supported bythe presence of 0.7% SDS, then Triton X-100 was added to a final
NIH P30 DK54759, for adenovirus purification. There are no potentialconcentration of 1% and pH was adjusted to 5.5 by adding 50 mM
financial conflicts of interest for any of the authors. This work wassodium acetate. The mixture was incubated with 100 mU of Vibrio
supported in part by the Muscular Dystrophy Association (K.P.C.)cholerae neuraminidase (Roche) and 2 mU of O-glycosidase (Roche)
and by US Public Health Service grant AI 45927 (S.K. and M.B.O).at 37C for 16 hr. The pH was neutralized by adding 100 mM sodium
K.P.C. is an investigator of the Howard Hughes Medical Institute.phosphate buffer and the mixture was then incubated with 10 mU
of N-glycosidase (Glyko) at 37C for 16 hr. Chemical deglycosylation
was performed as previously described (Ervasti and Campbell, Received: September 29, 2003
1993). Revised: March 9, 2004
Accepted: May 11, 2004
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